CompaniesPacgen Biopharmaceuticals Corporation

Pacgen Biopharmaceuticals Corporation

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (8)
View all

Total Trials

8

As Lead Sponsor

8

As Collaborator

0

Total Enrollment

519

By Phase

EARLY_PHASE1: 1PHASE1: 4PHASE2: 2PHASE3: 1

By Status

COMPLETED: 4RECRUITING: 3UNKNOWN: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details

Recent Trials

NCT06822998Lead Sponsor
HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors
EARLY_PHASE1Recruiting
10 participants
Started: Jun 11, 2025 · Completed: Jun 1, 2026
NCT05861895Lead Sponsor
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
PHASE1Recruiting
84 participants
Started: Dec 12, 2023 · Completed: Dec 22, 2025
NCT05388487Lead Sponsor
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
PHASE1Recruiting
54 participants
Started: Feb 16, 2022 · Completed: Nov 30, 2025
NCT05386823Lead Sponsor
Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers
PHASE1Completed
16 participants
Started: Mar 20, 2021 · Completed: Aug 4, 2021
NCT00659971Lead Sponsor
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
PHASE2Completed
223 participants
Started: Jan 31, 2008 · Completed: Jun 30, 2008
View all 8 trials →